Immunomodulatory actions of antibacterial agents

Clinical Immunotherapeutics

Volumn 6, Issue 6, 1996, Pages 454-464

  Labro, Marie Thérèse ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFODIZIME; ERYTHROMYCIN; ISONIAZID; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TROLEANDOMYCIN;

BACTERIAL INFECTION; CLINICAL TRIAL; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0029774003     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259367     Document Type: Review

References (99)

1. Drug resistance, Trends Microbiol 1994; 2 (10, Spec. Issue)
2. Friedman H, Klein TW, Yamaguchi H, editors, Microbial infections: role of biological response modifiers. Advances in experimental medicine and biology, vol. 319. New York, London: Plenum Press, 1992
3. Anderson JA, Franklin-Adkinson Jr N, Allergic reactions to drugs and biologic agents. JAMA 1987; 258: 2891-9
4. Pisciotta AV, Drug-induced agranulocytosis: peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4: 226-37
5. North RJ, Berche PA, Newborg MF, Immunologie consequences of antibiotic-induced abridgement of bacterial infection: effect on generation and loss of protective T cells and level of immunologie memory. J Immunol 1981 ; 127: 342-6
6. Pulverer G, Ko HL, Beuth J, Effets immunomodulateurs des antibiotiques influençant les flores digestifs. Path Biol 1993; 41:753-8
7. Labro MT, Host defence and infection. New York: Marcel Dekker, 1993
8. Weigent DA, Blalock JE, Associations between the neuroendocrine and immune systems. J Leukoc Biol 1995; 57: 137-50
9. Bellanti JA, Kadlec JV, Escobar-Gutierrez A, Cytokines and thé immune response. PediatrClin North Am 1994; 4l: 597-621
10. Klebanoff SJ, Clark RA, editors, The neutrophil. Function and clinical disorders. New York: North Holland, 1978
11. Gaur S, Kesarwala H, Gavai M, et al, Clinical immunology and infectious diseases. Pediatr Clin North Am 1994; 41: 745-82
12. Labro MT, Immunomodulation by antibacterial agents: is it clinically relevant? Drugs 1993; 45: 319-28
13. Ritts RE, Antibiotics as biological response modifiers. J Antimicrob Chemother 1990; 26 Suppl. C: 31-6
14. Labro MT, Effect of antimicrobial agents on polymorphonuclear neutrophil functions. In: Raoult D, editor. Antimicrobial agents and intracellular pathogens. Boca Raton: CRC Press, 1993:87-135
15. Labro MT, Interactions between antimicrobial drugs and phagocytes: an overview. Int J Antimicrob Agents 1993; 3: 73-87
16. Barrett JF, The immunomodulatory activities of anlibacterials. Exp Opin Invest Drugs 1995; 4: 551-7
17. Gemmell CG, Antibiotics and neutrophil function - potential immunomodulating activities. J Antimicrob Chemother 1993; 31 Suppl. B : 23
18. Labro MT, Experimental evaluation of antibiotic as immunomodulators. J Chemother 1994; 6 Suppl. 5: 10-14
19. Labro MT, Interaction entre les agents anti-infectieux et les phagocytes. Presse Med 1995; 24: 992-8
20. Lapenna D, Cellini L, De Gioca S, et al, Cephalosporins are scavengers of hypochlorous acid. Biochem Pharmacol 1995; 49: 1249-54
21. Günther MR, Mao J, Cohen MS, Oxidant-scavenging activities of ampicillin and sulbactam and their effects on neutrophil function. Antimicrob Agents Chemother 1993; 37: 950-6
22. Labro MT, El Benna J, Charlier N, et al, Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J Immunol 1994; 152: 2447-55
23. Labro MT, Abdelghaffar H, Cooper R, et al, Structure-activity relationships of new carbacephems with antioxidant properties [abstract]. In: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans: 925
24. Labro MT, Intraphagocytic penetration of macrolides. In: Bryskier A, Butzler JP, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: ArnetteBlackwell, 1993: 379-88
25. Labro MT, Effect of macrolides on host natural defences. In: Bryskier A, Butzler JP, Neu HC, et al., editors. Macrolides: chemistry, pharmacology and clinical uses. Paris: ArnetteBlackwell, 1993: 389-408
26. Abdelghaffar H, Mtairag EM, Labro MT, Effect of dirithromycin and erythromycylamine on human neutrophil degranulation. Antimicrob Agents Chemother 1994; 38: 1548-54
27. Labro MT, Abdelghaffar H, Douhet C, et al, Investigation of the mechanism underlying the stimulation of neulrophil (PMN) exocytosis by macrolides [abstract]. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco: G-39
28. Pascual A, Garcia I, Conejo MC, et al, Fluorometric and high performance liquid Chromatographie measurement of quinolone uptake by human neutrophils. Eur J Clin Microbiol Infect Dis 1991; 10: 969-71
29. Aoki M, Ono Y, Hunii O, et al, Effect of newer quinolones on the extra- and intra-cellular chemiluminescence response of human polymorphonuclear leucocytes. J Antimicrob Chemother 1994; 34: 383-90
30. Kubo S, Matsumoto T, Takahashi K, el al. Enhanced chemiluminescence response of polymorphonuclear leukocytes by new quinolone antimicrobials. Chemotherapy 1994: 40: 333-6
31. El Benna J, Hakim J. Labro MT. Inhibition of human neutrophil protein kinase C activity by the antimalarial drug mefloquine. Biochem Pharmacol 1992:43:527-32
32. Perry DK, Hand WL, Edmonson DE et al. Role of phospholipase D-derived diradyl glycerol in the activation of the human neutrophil respiratory burst oxidase. J Immunol 1992: 149:2749-58
33. Anderson R, Beyers AD, Savage J, et al. Apparent involvement of phospholipase A2 but not protein kinase C in the prooxidative interaction of clofazimine with human phagocytes. Biochem Pharmacol 1988: 37: 4635-41
34. Raoult D, editor, Antimicrobial agents and intracellular pathogens. Boca Raton: CRC Press. 1993
35. Silverstein SC, Kabbach C. Penetration, retention, intracellular localization and antimicrobial activity of antibiotics within phagocytes. Curr Opin Hematol 1994; 1: 85-91
36. Van Rensburg CEJ, Jooné G, Anderson R. Interactions of the oxygen-dependent antimicrobial system of the human neutrophil with difloxacin. ciprofloxacin, pefloxacin and fleroxacin in the intraphagocytic eradication of Sluphvlococciis miiviis. 1 Med Microbiol 1990: 32: 15-7
37. Anderson R, Van Rensburg CEJ, Jooné G, et al. An in vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J Antimicrob Chemother 1987: 20 Suppl. B: 57-68
38. Anderson R, Jooné G, Van Rensburg CEJ, An in vitro investigation of the intracellular bioactivity of amoxycillin. clinda mycin and erythromycin for Stiiphvlm-occn.'i mireus. J Infect Dis 1986; 153: 593-600
39. Mtairag EM, Abdelghaffar H, Douhet C. et al. Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides. Antimicrob Agents Chemother 1995; 39: 1676-82
40. Carlier MB, Garcia-Luque I, Montenez JP, et al, Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React 1994; 16: 211-20
41. Fontagne J, Roch-Arveiller M, Giroux JP, et al. Effect of some antimalarial drugs on rat inflammatory polymorphonuclear leucocyte function. Biomed Pharmacother 1989: 43: 443-51
42. Hart PD, Young MR, Manipulation of the phagosome-lysosome fusion response in cultured macrophages: enhancement of fusion by chloroquine and other amines. Exp Cell Res 1979; 114:486-90
43. Torigoe RK, The intracellular activity of ofloxacin and roxithromycin against Slaphylococcus anreiis phagocytosed in human neutrophils. Chemother Tokyo 1993; 41: 955-62
44. Labro MT, Cefodizime as a biological response modifier: a review7 of its in vivo. e\ vivo and /// viti'o immunomodulatory properties. J Antimicrob Chemother 1990: 26 Suppl. C: 37-47
45. Labro MT, Immunological evaluation of cefodizime: a unique molecule among cephalosporins. Infection 1992; 20 Suppl. I : S41-S44
46. Grassi C, Lower respiratory tract infections: clinical trials with a new cephalosporin. J Chemother 1994. 6 Suppl. 5: 28-9
47. Dammaco E, Benvestito S, Effects of cefodizime on non-specific immune functions in patients with multiple myeloma. Infection 1992: 20 Suppl. 1: S64-6
48. Meroni PL, Capsoni F, Borghi MO, et al. Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and c.v vivo studies. Infection 1992; 20 Suppl. I: S6I-3
49. Vanholder R, Dagrosa EE. Van Landschoot N. et al. Antibiotics and energy delivery to the phagocytosis-associated respiratory burst in chronic hemodialysis patients: a comparison of cefodizime and cotrimoxazole. Nephron 1993; 63: 65-72
50. Mallmann P, Briihl P. Immunological effects of cefodizime in patients underlying antineoplastic chemotherapy. Infection 1992:20Suppl. 1: S67-S70
51. Auteri A, Pasqui AL, Bruni F, et al. Effect of cefodizime (HR221) on immunological defects induced by surgical stress. Drugs Exp Clin Res 1991: 17: 555-61
52. Wenisch C, Parschalk B, Hasenhiindl M. et al. Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections. Antimicroh Agents Chemother 1995: 39: 672-6
53. Greenwald RA, Golub LM, Lavietes B. et al. Tetracyclines inhibit synovial collagenase in vim and in vitm. 3 Rheumatol 1987; 14: 28-32
54. Suomalainen K, Sorsa T. Golub L.M. et al. Specificity of the anticollagenase action of tetracyclines: relevance to their antiinflammatory potential. Antimicroh Agents Chemother 1992: 36: 227-9
55. Pruzanski W, Vadas P, Should tetracyclines he used in arthritis. J Rheumatol 1992: 19: 1495-7
56. El Attar TMA, Lin HS, Schulz R. 1988. Effect of minocycline on prostaglandin formation in gingival fibroblasts. J Periodonlal Res 1988:23: 285-6
57. Grec V, Frei PC. Effect of amoxycillin and doxycyclin on function of human granulocytes tested in vitro and on chemotaxis of granulocytes from rabbits given the two antibiotics. Inflammation'1984: 8: 417-27
58. Forsgren A, Schmeling D. Quie PG. Effect of tetracycline on the phagocytic function of human leukocytes. J Infect Dis 1974; 130:412-5
59. Gabler WL, Creamer HR, Suppression of human ncutrophil functions by tetracyclines. J Periodontal Res 1991; 26: 52-8
60. Wasil M, Halliwell B. Moorhouse CP. Scavenging of hypochlorous acid by letracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline. Biochem Phannacol 1988: 37: 775-8
61. Van Barr HMJ, Van De Kerkhof PCM. Mier PD, et al. Tetracyclines are potent scavengers of the Superoxide radical. Br J Dermatol 1987; 117: l31~-4
62. Sanchez 1, Tetracycline treatment in rheumatoid arthritis and other rheumatic diseases. Brasil Med 1968: 82: 22-31
63. Skinner M, Catheart ES, Mills JA. et al. Tetracycline in treatment of rheumatoid arthritis. Arthritis Rheum 1971; 14:727-32
64. Lauhio A, Eeirisalo-Repo M. Uihdevirta J. et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlutm-cliti urtliritix. Arthritis Rheum 1991: 34: 6-14
65. Eauhio A, Sorsa T. Lindy O. et al. The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum 1992: 35: 195-8
66. Tilley BC, Alarcon GS, Hey.se SP. et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo controlled trial. Ann Intern Med 1995: 122:81-9
67. Kloppenburg M, Breedveld FC, Terwiel J. et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994: 37: 629-36
68. Forestier J, Rheumatoid arthritis and its treatment by gold salts. Lancet 1934; II: 646-648
69. McConkey B, Situyanake D. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J Rheumatol 1988; 15: 46-50
70. Gabriel SE, Conn D, Luthra H, Rifampicin therapy in rheumatoid arthritis. J Rheumatol 1990; 17: 163-6
71. Cox NL, Prowse M V, Maddison MC, et al, Treatment of early rheumatoid arthritis with rifampicin. Ann Rheum Dis 1992; 51: 32-4
72. Caruso I, Boccassini L, Cazzola M, et al, Multilocal intraarticular treatment of rheumatoid arthritis: a randomized prospective study comparing rifamycin SV with pefloxacin. J Int Med Res 1992; 20: 27-39
73. Caruso l, Santandrea S, Sarzi Puttini P, et al, Prevention of appearance of radiologie lesions in early rheumatoid arthritis: a randomized single-blind study comparing intra-articular rifamycin with auranofin in 116 patients followed for 60 months. J Int Med Res 1992; 20: 61-77
74. Caruso I, Cazzola M, Santandrea S, Clinical improvement in ankylosis spondylitis with rifamycin SV infiltrations of peripheral joints. J Int Med Res 1992; 20: 171-81
75. Caruso I, Montrone F, Fumagalli M, et al, Rifamycin SV in the treatment of knee synovitis. Orthopedics 1982; 5: 1336-43
76. Caruso 1, Principi N, D'Urbino G, et al, Rifamycin SV administered by intraarticular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis. J Int Med Res 1993; 21: 243-56
77. Nessi R, Pallanza R, Fowst G, Rifampicin and immunosuppression. Arzneimittel Forschung 1974; 24: 832-6
78. Gray CD, Wayne-Smith C, Hollers JC, et al, Rifampicin affects polymorphonuclear leukocyte interactions with bacterial and synthetic chemotaxis but not interactions with serum-derived chemotaxins. Antimicrob Agents Chemother 1993; 24: 777-83
79. Höger PH, Vosbeck K, Seger R, et al, Uptake, intracellular activity and influence of rifampin on normal function of polymorphonuclear leukocytes. Antimicrob Agents Chemother 1985; 28: 667-74
80. Zeis BM, Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro. Chemotherapy 1988; 34: 56-60
81. Kenny MT, Torney HL, Balistreri FJ, Comparative effect of the naphthalenic ansamycin, rifamycin SV, rifampin and cyclopentyl rifampicin on murine neutrophil function. Int J Immunopharmacol 1989; 11:915-20
82. Itkin IH, Menzel ML, The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970;45:146-62
83. Spector SL, Katz FH, Farr RS, Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin Immunol 1974; 54: 367-79
84. Plewig G, Schöpf E, Anti-inflammatory effects of antimicrobial agents. Drugs 1976; II: 472-3
85. Miyatake H, Taki F, Taniguchi H, et al, Erythromycin reduces the severity of bronchial hyperresponsivenness in asthma. Chest 1991; 99: 670-3
86. Nagai H, Shishido H, Yoneda R, et al, Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-9
87. Agen C, Danes! R, Blandizzi C, et al, Macrolide antibiotics as anti-inflammatory agents: roxithromycin in an unexpected role. Agents Actions 1993; 38: 85-90
88. Mikasa K, Kita E, Sawaki M, et al, The anti-inflammalory effect of erythromycin in zymosan-induced peritonitis of mice. J Antimicrob Chemother 1992; 30: 339-48
89. Tamaoki J, Sakai N, Tagaya E, et al, Macrolide antibiotics protect against endotoxin-induced vascular leakage and neutrophil accumulation in rat trachea. Antimicrob Agents Chemother 1994:38: 1641-3
90. Labro MT, El Benna J, Babin-Chevaye C, Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24: 561 -72
91. JoonéGK, Van Rensburg CEJ, Andersen R, Investigation of the in vitro uptake, intraphagocytic biological activity and effects on neutrophil Superoxide generation of dirithromycin compared with erythromycin. J Antimicrob Chemother 1992; 30: 509-23
92. Anderson R, Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated Superoxide generation and autooxidation. J Infect Dis 1989; 159:966-73
93. Labro MT, El Benna J, Barré J, Effect of roxithromycin (ROX) and erythromycin (ERY) on human neutrophil (PMN) functions ex vivo [abstract]. First International Conference Macrolides, Azalides and Streptogramins. 1992 Jan 22-25; Santa Fe(NM):A175
94. Bailly S, Pocidalo JJ, Fay M, et al, Differential modulation of cytokine production by macrolides: interleukin-6 production is increased by spiramycin and erythromycin. Antimicrob Agents Chemother 1991; 35: 2016-9
95. Kita E, Sawaki M, Mikasa K, et al, Alterations of host response by a long term treatment of roxithromycin. J Antimicrob Chemother 1993; 32: 285-94
96. Konno S, Actachi M, Asano K, et al, Anti-allergic activity of roxithromycin: inhibition of interleukin-5 production from mouse T lymphocytes. Life Sei 1993; 52: 25-30
97. Kadota JI, Non-antibiotic effect of antibiotics. Clin Microbiol Infect 1995; 1 Suppl. 2: S20-2
98. Kita E, Sawaki M, Oku D, et al, Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991; 27: 273-84
99. Hirakata Y, Kahn M, Mizukane R, et al, Potential effects of erythromycin on host defence systems and virulence of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 1922-7